Altimmune Announces $14 million Registered Direct Offering
March 08, 2019 09:29 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., March 08, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced it has entered into a purchase agreement with two...
Altimmune Announces Presentation of HepTcell Phase 1 Results at The International Liver Congress™ in Vienna, Austria
January 29, 2019 08:00 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., Jan. 29, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced results of its recently completed HepTcell Phase 1...
Altimmune Announces Clinical Program Updates and Plans for Pipeline Expansion
December 13, 2018 07:01 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., Dec. 13, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced updates to its clinical programs and plans to further...
Altimmune Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 30, 2018 18:06 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., Nov. 30, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ: ALT), a clinical-stage immunotherapeutics company, granted equity awards on November 30, 2018, that were previously...
Altimmune Appoints Vipin K. Garg, Ph.D. as its New President and Chief Executive Officer
November 27, 2018 09:00 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced the appointment of Vipin K. Garg, Ph.D. as its...
Altimmune Announces Third Quarter 2018 Financial Results and Provides Corporate Update
November 13, 2018 16:50 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced financial results for the three and nine months ended...
Altimmune to Present at Dawson James Securities 4th Annual Small Cap Growth Conference
October 26, 2018 11:29 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., Oct. 26, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced that Bill Enright, President and Chief Executive...
Altimmune Announces $25 million Registered Direct Offering
October 08, 2018 09:00 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., Oct. 08, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced it has entered into a purchase agreement with several...
Altimmune Closes on $16.9 Million in Funding
October 03, 2018 08:00 ET
|
Altimmune, Inc.
$12 million underwritten public offering closed October 2$4.9 million registered direct offering closed September 26 GAITHERSBURG, Md., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:...
Altimmune Announces Pricing of $12 Million Underwritten Public Offering
September 28, 2018 09:01 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., Sept. 28, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced the pricing of an underwritten public offering of...